GHENT, Belgium, 20 February 2014 - Ablynx [Euronext Brussels: ABLX] will announce its full year results for 2013 on Thursday 27 February 2014 at 7.00 am CET.
The Ablynx management team will host a conference call and webcast during which the full year results for 2013 and outlook for 2014 will be presented, followed by a Q&A session. This event will be held on Thursday 27 February 2014 at 4.00 pm CET/10.00 am EST.
The conference call will be webcast live and may be accessed on the home page of the Ablynx website at www.ablynx.com:
http://www.ablynx.com/ or by clicking here:
http://www.media-server.com/m/p/4pp3kiyz. If you would like to participate in the Q&A session, please dial +32 (0) 2 620 01 38, confirmation code 8682086. Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under the news & events>past events page:
http://www.ablynx.com/en/news-press/past-events-presentations/.
About Ablynx
Ablynx:
http://www.ablynx.com/ is a biopharmaceutical company engaged in the discovery and development of Nanobodies®:
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 30 programmes in the pipeline:
http://www.ablynx.com/en/research-development/pipeline/ and seven Nanobodies in clinical development. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com:
http://www.ablynx.com/.
For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com:
mailto:marieke.vermeersch@ablynx.com%20
Follow us on Twitter @AblynxABLX
Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx@consilium-comms.com:
mailto:ablynx@consilium-comms.com
http://hugin.info/137912/R/1763190/597409.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire